SCHEMBL7000183

SCHEMBL7000183

Cn1cc2c(=O)n(Cc3ccc(F)cc3)cnc2n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.51
HTT P42858 1/20 0.51
KDM4E B2RXH2 4/20 0.51
ALDH1A1 P00352 1/20 0.51
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
LMNA P02545 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MMP13 P45452 1/20 0.44
GAA P10253 1/20 0.44
PKM P14618 1/20 0.44
HPGD P15428 1/20 0.44
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7003576 0.88 LMNA (0.48) SMN1; SMN2HTTKDM4EMEN1KMT2A
SCHEMBL7081478 0.88 TP53 (0.52) MEN1KMT2ALMNAHDAC6
SCHEMBL7003827 0.86 SMN1; SMN2 (0.49) SMN1; SMN2KDM4ELMNAL3MBTL1GAA
SCHEMBL7002718 0.86 TRPA1 (0.48) SMN1; SMN2KDM4EALDH1A1MMP13
SCHEMBL7077434 0.85 KDM4E (0.45) KDM4EALDH1A1L3MBTL1MMP13HPGD
SCHEMBL6997875 0.81 CHRM1 (0.52) HTTKDM4EALDH1A1KMT2ALMNA
SCHEMBL6997073 0.80 FSCN1 (0.54) SMN1; SMN2HTTALDH1A1L3MBTL1MMP13
SCHEMBL7002192 0.79 HPGD (0.49) SMN1; SMN2HTTALDH1A1MEN1KMT2A
SCHEMBL7077791 0.78 TSHR (0.58) SMN1; SMN2HTTKDM4EALDH1A1MEN1
SCHEMBL7077867 0.78 TSHR (0.47) SMN1; SMN2HTTKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186997-A1 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same ELBION AG (DE) 2003-10-02 US claimed
US-20030186997-A1 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same ELBION AG (DE) 2003-10-02 US disclosed
EP-1311510-A1 2,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES WITH AN ANTICONVULSIVE ACTION AND METHODS FOR PRODUCING THE SAME ARZNEIMITTELWERK DRESDEN GMBH (DE) 2003-05-21 EP disclosed
WO-2002018387-A1 2,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES WITH AN ANTICONVULSIVE ACTION AND METHODS FOR PRODUCING THE SAME ELBION AG (DE) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186997-A1 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same DDO, GRIN3A, GRIK4 SMN1; SMN2 861/4885HTT 668/4885KDM4E 1874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.